EQRx gets MAA for aumolertinib accepted by EMA

The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for aumolertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI).

The drug is being developed by Cambridge, USA-based EQRx (Nasdaq: EQRX), which describes itself as a new type of pharmaceutical company committed to developing and expanding access to more affordable innovative medicines for some of the most prevalent disease areas, and promising a radical disruption of pricing. However, the company has recently faced up to a dose of reality, that speaks more of realism and maximizing shareholder value. The company reported a net loss of $82.5 million for the three months ended June 30, 2022.

Aumolertinib is in development for the first-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations, and for adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.